Table 2.

Patient characteristics of GBS cases documented in England occurring within 6 weeks of first dose COVID-19 vaccination with specific breakdown of gender and age for ChAdOx1 nCoV-19 and tozinameran recipients

Patient characteristics		Cases	Estimated first dose vaccinations (million)	Estimated 6-week GBS case rate (/100 000 first doses)	95% CI
Gender	Female	76	17.0	0.448	0.358–0.560
	Male	120	15.1	0.795	0.665–0.951
Age group, years	18–29	7	2.0	0.355	0.172–0.732
	30–39	16	3.9	0.415	0.255–0.674
	40–49	33	5.9	0.557	0.396–0.782
	50–59	54	7.1	0.762	0.584–0.994
	60–69	51	5.7	0.890	0.677–1.170
	70–79	33	4.7	0.699	0.498–0.982
	80+	4	2.8	0.145	0.056–0.372
Vaccine	ChAdOx1 nCoV-19	176	20.3	0.868	0.749–1.006
	Tozinameran	21	11.5	0.183	0.120–0.280
	mRNA-1273	1	0.3	0.325	0.057–1.844
ChAdOx1 nCoV-19 only
Gender	Female	68	10.4	0.656	0.517–0.831
	Male	106	9.9	1.069	0.884–1.293
Age, years	18–29	4	1.1	0.380	0.148–0.977
	30–39	16	1.6	0.986	0.607–1.601
	40–49	30	4.4	0.683	0.478–0.975
	50–59	50	5.6	0.899	0.682–1.185
	60–69	48	4.0	1.196	0.902–1.586
	70–79	28	2.8	1.007	0.697–1.455
	80+	0	0.9	–	–
Tozinameran only
Gender	Female	7	6.5	0.108	0.052–0.224
	Male	14	5.0	0.280	0.167–0.470
Age	18–29	3	0.9	0.332	0.113–0.976
	30–39	0	2.1	–	–
	40–49	2	1.4	0.147	0.040–0.538
	50–59	4	1.5	0.264	0.103–0.678
	60–69	3	1.7	0.175	0.059–0.514
	70–79	5	1.9	0.258	0.110–0.604
	80+	4	1.9	0.210	0.082–0.539

Note mRNA-1273 recipients were not separately analysed due to only a single case being reported.